Aurobindo Pharma | Sustainability Performance
Manufactures generic pharmaceuticals and active pharmaceutical ingredients.
1986
India
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#11224
Overallⓘ#341
in Indiaⓘ#267
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Critical
Aligned
Laggard
Controversy level
- Aurobindo Pharma Limited, Indian major generic pharma, has faced sustained US FDA enforcement scrutiny including the historic 20192024 sustained Aurobindo Form 483 warning letters at multiple Indian Hyderabad/Telangana API and finished dose facilities with multiple US FDA Import Alerts affecting Aurobindo's US ANDA generic pipeline, plus periodic class actions over alleged inadequate disclosure of US FDA compliance affecting Indian institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.